CEL-SCI Corporation reported a net operating loss of USD 5.4 million for the three months ended December 31, 2025. General and administrative expenses decreased by 31% to USD 1.8 million in the same period, primarily due to lower employee stock compensation, reduced public relations costs, and lower accounting and legal fees. Net interest expense fell by 47% to USD 0.1 million. The company disclosed substantial doubt about its ability to continue as a going concern due to accumulated losses, expected continued future losses, and limited cash balances. CEL-SCI highlighted that its ability to proceed with clinical trials and research depends on available capital and regulatory approvals, which remain outstanding for its development-stage projects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-001319), on February 17, 2026, and is solely responsible for the information contained therein.